Coagulation disorders during treatment with cefazolin and rifampicin: rare but dangerous

Coagulation disorders during treatment with cefazolin and rifampicin: rare but dangerous

<p>We describe a 79-year-old man with spondylodiscitis and unknown pathogen, treated with cefazolin and rifampicin. He developed a massive digestive hemorrhage. Prothrombin time was prolonged with severe vitamin-K-dependent clotting-factor deficiency. Severe bleeding can occur during cefazolin...

Full description

Bibliographic Details
Main Authors: I. Kouki, C. Montagner, W. Mauhin, J. London, T. Lazard, S. Grimbert, V. Zeller, O. Lidove
Format: Article
Language:English
Published: Copernicus Publications 2021-04-01
Series:Journal of Bone and Joint Infection
Online Access:https://jbji.copernicus.org/articles/6/131/2021/jbji-6-131-2021.pdf
id doaj-dfb4edcb1fdf4238a92dd7dfb8b1f302
record_format Article
spelling doaj-dfb4edcb1fdf4238a92dd7dfb8b1f3022021-04-01T05:42:04ZengCopernicus PublicationsJournal of Bone and Joint Infection2206-35522021-04-01613113410.5194/jbji-6-131-2021Coagulation disorders during treatment with cefazolin and rifampicin: rare but dangerousI. Kouki0C. Montagner1W. Mauhin2J. London3T. Lazard4S. Grimbert5V. Zeller6O. Lidove7Service de Médecine Interne, Groupe Hospitalier Diaconesses – Croix Saint-Simon, 125 rue d'Avron, 75020, Paris, FranceService de Médecine Interne, Groupe Hospitalier Diaconesses – Croix Saint-Simon, 125 rue d'Avron, 75020, Paris, FranceService de Médecine Interne, Groupe Hospitalier Diaconesses – Croix Saint-Simon, 125 rue d'Avron, 75020, Paris, FranceService de Médecine Interne, Groupe Hospitalier Diaconesses – Croix Saint-Simon, 125 rue d'Avron, 75020, Paris, FranceService de Réanimation, Groupe Hospitalier Diaconesses – Croix Saint-Simon, 125 rue d'Avron, 75020, Paris, FranceService de Gastro-entérologie et Endoscopies Digestives, Groupe Hospitalier Diaconesses – Croix Saint-Simon, 125 rue d'Avron, 75020, Paris, FranceCentre de Référence des Infections Ostéo-articulaires, Groupe Hospitalier Diaconesses – Croix Saint-Simon, 125 rue d'Avron, 75020, Paris, FranceService de Médecine Interne, Groupe Hospitalier Diaconesses – Croix Saint-Simon, 125 rue d'Avron, 75020, Paris, France<p>We describe a 79-year-old man with spondylodiscitis and unknown pathogen, treated with cefazolin and rifampicin. He developed a massive digestive hemorrhage. Prothrombin time was prolonged with severe vitamin-K-dependent clotting-factor deficiency. Severe bleeding can occur during cefazolin and rifampicin use. This deficiency should be assessed before prescribing cefazolin–rifampicin and prothrombin time monitored.</p>https://jbji.copernicus.org/articles/6/131/2021/jbji-6-131-2021.pdf
collection DOAJ
language English
format Article
sources DOAJ
author I. Kouki
C. Montagner
W. Mauhin
J. London
T. Lazard
S. Grimbert
V. Zeller
O. Lidove
spellingShingle I. Kouki
C. Montagner
W. Mauhin
J. London
T. Lazard
S. Grimbert
V. Zeller
O. Lidove
Coagulation disorders during treatment with cefazolin and rifampicin: rare but dangerous
Journal of Bone and Joint Infection
author_facet I. Kouki
C. Montagner
W. Mauhin
J. London
T. Lazard
S. Grimbert
V. Zeller
O. Lidove
author_sort I. Kouki
title Coagulation disorders during treatment with cefazolin and rifampicin: rare but dangerous
title_short Coagulation disorders during treatment with cefazolin and rifampicin: rare but dangerous
title_full Coagulation disorders during treatment with cefazolin and rifampicin: rare but dangerous
title_fullStr Coagulation disorders during treatment with cefazolin and rifampicin: rare but dangerous
title_full_unstemmed Coagulation disorders during treatment with cefazolin and rifampicin: rare but dangerous
title_sort coagulation disorders during treatment with cefazolin and rifampicin: rare but dangerous
publisher Copernicus Publications
series Journal of Bone and Joint Infection
issn 2206-3552
publishDate 2021-04-01
description <p>We describe a 79-year-old man with spondylodiscitis and unknown pathogen, treated with cefazolin and rifampicin. He developed a massive digestive hemorrhage. Prothrombin time was prolonged with severe vitamin-K-dependent clotting-factor deficiency. Severe bleeding can occur during cefazolin and rifampicin use. This deficiency should be assessed before prescribing cefazolin–rifampicin and prothrombin time monitored.</p>
url https://jbji.copernicus.org/articles/6/131/2021/jbji-6-131-2021.pdf
work_keys_str_mv AT ikouki coagulationdisordersduringtreatmentwithcefazolinandrifampicinrarebutdangerous
AT cmontagner coagulationdisordersduringtreatmentwithcefazolinandrifampicinrarebutdangerous
AT wmauhin coagulationdisordersduringtreatmentwithcefazolinandrifampicinrarebutdangerous
AT jlondon coagulationdisordersduringtreatmentwithcefazolinandrifampicinrarebutdangerous
AT tlazard coagulationdisordersduringtreatmentwithcefazolinandrifampicinrarebutdangerous
AT sgrimbert coagulationdisordersduringtreatmentwithcefazolinandrifampicinrarebutdangerous
AT vzeller coagulationdisordersduringtreatmentwithcefazolinandrifampicinrarebutdangerous
AT olidove coagulationdisordersduringtreatmentwithcefazolinandrifampicinrarebutdangerous
_version_ 1724176874233397248

Similar Items